Acipimox stimulates skin blood flow by a cyclo-dxygenase-dependent mechanism
- 1 October 1990
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 39 (1) , 37-41
- https://doi.org/10.1007/bf02657054
Abstract
The blood flow in the skin and the urinary excretion of the PGI2 metabolite 2,3-dinor-6-keto-PGF1a (PGI-M) were determined in the nine healthy subjects randomly assigned to double-blind oral treatment with a) placebo and acipimox (AC) 500 mg, b) acetylsalicylic acid 1500 mg and AC 500 mg, or c) placebo and nicotinic acid (NIC) 500 mg, on three different occasions. After treatment with placebo and AC there was a transient increase in the skin blood flow, up to about fourtimes the basal level, and a concomitant increase in skin temperature. After acetylsalicylic acid and AC no increase in skin flow rate or temperature was found. Urinary excretion of PGI-M was insignificantly increased by AC, but fell after acetylsalicylic acid pretreatment. NIC elicited a more marked increase in skin blood flow than AC, and in parallel the urinary excretion of PGI-M was more than doubled. It is concluded that cutaneous flushing induced by AC is cyclo-oxygenase dependent. In comparison to NIC, however, AC appears as a weak stimulant of vascular prostacyclin formation.This publication has 18 references indexed in Scilit:
- Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man.Journal of Clinical Investigation, 1989
- Clinical Implications of Prostaglandin and Thromboxane A2FormationNew England Journal of Medicine, 1988
- A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemiaAtherosclerosis, 1985
- Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man.Circulation, 1985
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- Bioavailability and Pharmacokinetics in Man of Acipimox, a New Antilipolytic and Hypolipemic AgentJournal of International Medical Research, 1981
- Prostaglandins contribute to the vasodilation induced by nicotinic acidProstaglandins, 1979
- Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like DrugsNature New Biology, 1971
- Influence of nicotinic acid on serum cholesterol in manArchives of Biochemistry and Biophysics, 1955